Address Needs
Significant Unmet Need and Global Healthcare Burden
Chronic Wounds
2014: $96B (Medicare alone)
Traumatic Open Soft Tissue Wounds
2020: >$1B
Scar Treatments
2023: (predicted) $32B
Osteoarthritis
(cartilage regeneration)
$34.5 million nationally, $237 million worldwide, $4.8B Global cartilage repair market in 2018
Cosmetic Surgeries
Global $50B by 2027
Conditions such as diabetic foot ulcers, severe burns, surgical wounds, and traumatic injuries often heal slowly and can result in scarring that compromises long-term tissue function.
There are currently no FDA-approved small molecule therapies for chronic wounds or scar reduction, representing a significant unmet medical need and substantial market opportunity.
By shifting repair toward regenerative restoration, therapies derived from Eluciderm's platform may have applications across several large medical markets, including:
-
chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers
-
burn and trauma injuries
-
surgical complications: wound dehiscence, post-procedural infection and scarring complications
-
primary surgical repair and invasive procedures
-
inhalation injury and pulmonary fibrosis
-
cartilage regeneration
-
unmet oncological targets: leukemia, melanoma
-
cosmesis and tissue regeneration
Restore Lives
Healing Shapes Life After Injury
For many, recovery includes lasting reminders. Scar tissue, reduced mobility, chronic wounds, and the emotional weight that comes with them. Eluciderm points toward a different experience. One where healing is more complete, and the body returns closer to its original state.
Better healing changes how people move through the world. It supports independence, resilience, and long-term well-being.
The impact of Eluciderm’s regenerative approach extends far beyond wound closure. People recover with greater mobility, confidence, independence, and quality of life. Surgical patients may heal with fewer visible and physical limitations, while individuals living with chronic wounds face fewer complications and disruptions over time.
Designed as a portable spray-on therapy, ELU42 has the potential to bring regenerative healing to more people in more places, from hospitals and clinics to homes and remote environments.
By restoring the body’s capacity for organized repair, Eluciderm aims to give people back what injury often takes away.
